Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05546515 · ClinicalTrials.gov registry record · Phase 2
Suvorexant for Opioid/Stimulant Co-use
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT05546515: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT05546515 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05546515, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will evaluate whether Suvorexant 20mg reduces drug use and craving, and improves sleep and stress among persons with co-occurring opioid use disorder and stimulant use disorder.
Interventions
- DRUG Placebo
- DRUG Suvorexant (dual orexin receptor antagonist)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-12-01 |
| Est. Completion | 2024-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05546515
The ClinicalTrials.gov registry entry for NCT05546515 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05546515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05546515 about?
NCT05546515 is a clinical study titled "Suvorexant for Opioid/Stimulant Co-use". This study will evaluate whether Suvorexant 20mg reduces drug use and craving, and improves sleep and stress among persons with co-occurring opioid use disorder and stimulant use disorder.
What is the current status of trial NCT05546515?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2022-12-01. Estimated completion is 2024-11-30.
What interventions are being tested in trial NCT05546515?
The interventions under investigation include: Placebo (DRUG), Suvorexant (dual orexin receptor antagonist) (DRUG).
Who is sponsoring clinical trial NCT05546515?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.